Form 4: Century Therapeutics CEO Sells Shares for Tax Obligations

Century Therapeutics CEO Brent Pfeiffenberger disposed of 55,397 common shares to cover tax liabilities related to restricted stock unit vesting.

Summary

• Brent Pfeiffenberger, President and CEO, and a Director of Century Therapeutics, Inc. (IPSC), reported a transaction on March 11, 2026.
• The transaction involved the disposition of 55,397 shares of common stock at a price of $2.73 per share.
• These shares were withheld by Century Therapeutics to satisfy tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Pfeiffenberger directly beneficially owns 3,710,958 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a non-discretionary transaction for tax purposes rather than a discretionary sale or purchase reflecting a change in sentiment towards the company.

Positives

• The transaction represents a non-discretionary sale to cover tax liabilities, which is a routine event for executives receiving equity compensation and does not indicate a lack of confidence in the company.

Negatives

• The transaction represents a non-discretionary sale to cover tax liabilities, which is a routine event for executives receiving equity compensation and does not indicate a negative outlook on the company.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insiders, providing transparency into their ownership changes. This specific filing details a non-discretionary transaction common for executives receiving equity compensation.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary sale of shares by the CEO to cover tax obligations associated with restricted stock unit vesting. Such transactions are common and do not typically signal a change in the insider's confidence in the company or warrant a change in investment recommendation based solely on this event. Therefore, a "hold" recommendation is appropriate as this filing provides no new information to alter an existing investment thesis.

Keywords

Century Therapeutics, IPSC, Brent Pfeiffenberger, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, CEO, Director